Is Avacta Group Plc (AVCTF) a Buy, Sell, or Hold?
OTC : AVCTF
Avacta Group Plc — News
$0.9064 USD
$0 (0.0%)
- Volume
- 12K
- Average Volume
- 10.38K
- Market Capitalization
- $424.56M
- P/E Ratio
- -7.52
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.23
- Year Low
- $0.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.89
| Source | Headline |
|---|---|
|
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. globenewswire.com - 2026-07-08 02:00:00 |
|
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON and PHILADELPHIA, June 01, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today released updated Phase 1a/1b and pharmacokinetics (PK), safety, toxicity and preliminary efficacy data with faridoxorubicin (AVA6000, pre|CISION®-enabled doxorubicin) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Christina Coughlin, CEO of Avacta, commented: "Today's data further underscores our confidence in both our Gen One product faridoxorubicin (AVA6000) and our pre|CISION ® technology to significantly improve treatment options for cancer patients. globenewswire.com - 2026-06-01 02:00:00 |
|
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript seekingalpha.com - 2026-05-25 16:47:05 |
|
Unaudited Preliminary Results for the Year Ended December 31, 2025
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25"). globenewswire.com - 2026-05-19 02:14:00 |
|
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event. globenewswire.com - 2026-05-06 02:00:00 |
